An official website of the United States government
Home
Name
Brentuximab vedotin
Alternate Names
Adcetris
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
Antibody-drug conjugate
(ADC)
NSC Number
None
Primary Site
Hodgkin Lymphoma
Histology
Remarks
November 10, 2022 FDA approved brentuximab vedotin (Adcetris) in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide for pediatric patients 2 years of age and older with previously untreated high risk classical Hodgkin lymphoma (cHL). This is the first pediatric approval for brentuximab vedotin.
11/16/2018: Today, the U.S. Food and Drug Administration expanded the approved use of Adcetris (brentuximab vedotin) injection in combination with chemotherapy for adult patients with certain types of peripheral T-cell lymphoma (PTCL). This is the first FDA approval for treatment of newly diagnosed PTCL, and the agency used a new review program to complete the approval more quickly.
November 9, 2017: FDA granted regular approval to brentuximab vedotin for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.
The FDA approved brentuximab vedotin, brand name Adcetris, for the treatment of HL (Hodgkin lymphoma) and ALCL (systemic anaplastic large cell lymphoma). Adcetris consists of a drug and an antibody: an antibody-drug conjugate. The antibody directs the drug to CD30, a target on lymphoma cells. Adectris was approved under the FDA's accelerated approval program. Adcetris is designed for individuals whose Hodgkin lymphoma continued to progress after autologous stem cell transplant, or after two previous treatments with chemotherapy and the patient cannot receive a transplant. Adectris can also be prescribed for individuals whose ALCL has progressed after one treatment with chemotherapy.
March 20, 2018: FDA approved brentuximab vedotin (Adcetris) to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy.
11/16/2018: Today, the U.S. Food and Drug Administration expanded the approved use of Adcetris (brentuximab vedotin) injection in combination with chemotherapy for adult patients with certain types of peripheral T-cell lymphoma (PTCL). This is the first FDA approval for treatment of newly diagnosed PTCL, and the agency used a new review program to complete the approval more quickly.
November 9, 2017: FDA granted regular approval to brentuximab vedotin for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.
The FDA approved brentuximab vedotin, brand name Adcetris, for the treatment of HL (Hodgkin lymphoma) and ALCL (systemic anaplastic large cell lymphoma). Adcetris consists of a drug and an antibody: an antibody-drug conjugate. The antibody directs the drug to CD30, a target on lymphoma cells. Adectris was approved under the FDA's accelerated approval program. Adcetris is designed for individuals whose Hodgkin lymphoma continued to progress after autologous stem cell transplant, or after two previous treatments with chemotherapy and the patient cannot receive a transplant. Adectris can also be prescribed for individuals whose ALCL has progressed after one treatment with chemotherapy.
March 20, 2018: FDA approved brentuximab vedotin (Adcetris) to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy.
Coding
This drug should be coded
